TGFB1 and neoplasm: These results suggest that DC/CAF fusion cells can stimulate T cells and may serve as a new type of anti‐tumour immune vaccine.105 Gottschalk et al developed a new compound DC vaccine (DC‐shA20‐FAP‐TRP2) that targeted FAP and tumour antigen tyrosine‐related protein 2 (TRP‐2).106 The vaccine enhanced the tumour infiltration of CD8+ T cells and induced antigen diffusion, leading to effective anti‐tumour activity.106 Mice that were treated with anti‐CAF exhibited lower TGF‐β expression in the TME.